A three-dimensional quantitative structure-activity relationship study of the inhibition of the ATPase activity and the strand passing catalytic activity of topoisomerase IIα by substituted purine analogs

Molecular Pharmacology

Volumn 70, Issue 5, 2006, Pages 1503-1513

  Jensen, Lars H ^a,b   Liang, Hong ^d   Shoemaker, Robert ^c   Grauslund, Morten ^a   Sehested, Maxwell ^b   Hasinoff, Brian B ^d  

^a BioAlliance Pharma   (France)

^b Mental Health Services CPH   (Denmark)

^c NATIONAL CANCER INSTITUTE   (United States)

^d UNIVERSITY OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE; ADENOSINE TRIPHOSPHATASE INHIBITOR; DNA; DNA TOPOISOMERASE (ATP HYDROLYSING); ETOPOSIDE; GYRASE INHIBITOR; NSC 19865; NSC 348400; NSC 348401; NSC 348402; NSC 35866; NSC 39055; PURINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CATALYSIS; CONTROLLED STUDY; CYTOTOXICITY; DNA STRAND; DRUG ACTIVITY; DRUG POTENCY; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE STRUCTURE ACTIVITY RELATION; THREE DIMENSIONAL IMAGING;

ADENOSINE TRIPHOSPHATASES; ANTIGENS, NEOPLASM; CATALYSIS; CELL LINE; DNA; DNA BREAKS, DOUBLE-STRANDED; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; ELECTROSTATICS; ENZYME INHIBITORS; ETOPOSIDE; HCT116 CELLS; HUMANS; HYDROPHOBICITY; INHIBITORY CONCENTRATION 50; MODELS, MOLECULAR; MUTANT PROTEINS; PIPERAZINES; PURINES; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; RAZOXANE;

EID: 33751172757     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.106.026856     Document Type: Article

References (32)

1. Adachi N, Suzuki H, Iiizumi S, and Koyama H (2003) Hypersensitivity of nonhomologous DNA end-joining mutants to VP-16 and ICRF-193: implications for the repair of topoisomerase II-mediated DNA damage. J Biol Chem 278:35897-35902.
2. Akimitsu N, Adachi N, Hirai H, Hossain MS, Hamamoto H, Kobayashi M, Aratani Y, Koyama H, and Sekimizu K (2003) Enforced cytokinesis without complete nuclear division in embryonic cells depleting the activity of DNA topoisomerase IIα. Genes Cells 8:393-402.
3. Andoh T and Ishida R (1998) Catalytic inhibitors of topoisomerase II. Biochim Biophys Acta 1400:155-171.
4. Baldwin EL, Byl JA, and Osheroff N (2004) Cobalt enhances DNA cleavage mediated by human topoisomerase II alpha in vitro and in cultured cells. Biochemistry 43:728-735.
5. Classen S, Olland S, and Berger JM (2003a) Structure of the topoisomerase II ATPase region and its mechanism of inhibition by the chemotherapeutic agent ICRF-187 [published erratum appears in Proc Natl Acad Sci USA 100:14510, 2003]. Proc Natl Acad Sci USA 100:10629-10634.
6. Cramer RD III, Patterson DE, and Bunce JD (1988) Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. J Am Chem Soc 110:5959-5967.
7. Hasinoff BB, Wu X, Begleiter A, Guziec L, Guziec F, Giorgianni A, Yang S, Jiang Y, and Yalowich JC (2006) Structure-activity study of the interaction of bioreductive benzoquinone alkylating agents with DNA topoisomerase II. Cancer Chemother Pharmacol 57:221-233.
8. Hasinoff BB, Wu X, Krokhin OV, Ens W, Standing KG, Nitiss JL, Sivaram T, Giorgianni A, Yang S, Jiang Y, et al. (2005) Biochemical and proteomics approaches to characterize topoisomerase IIα cysteines and DNA as targets responsible for cisplatin-induced inhibition of topoisomerase IIα. Mol Pharmacol 67:937-947.
9. Hofland KF, Thougaard AV, Dejligbjerg M, Jensen LH, Kristjansen PE, Rengtved P, Sehested M, and Jensen PB (2005) Combining etoposide and dexrazoxane synergizes with radiotherapy and improves survival in mice with central nervous system tumors. Clin Cancer Res 11:6722-6729.
10. Holm B, Sehested M, and Jensen PB (1998) Improved targeting of brain tumors using dexrazoxane rescue of topoisomerase II combined with supralethal doses of etoposide and teniposide. Clin Cancer Res 4:1367-1373.
11. Holm C, Goto T, Wang JC, and Botstein D (1985) DNA topoisomerase II is required at the time of mitosis in yeast. Cell 41:553-563.
12. Jensen LH, Renodon-Corniere A, Wessel I, Langer SW, Sokilde B, Carstensen EV, Sehested M, and Jensen PB (2002) Maleimide is a potent inhibitor of topoisomerase II in vitro and in vivo: a new mode of catalytic inhibition. Mol Pharmacol 61:1235-1243.
13. Jensen LH, Thougaard AV, Grauslund M, Sokilde B, Carstensen EV, Dvinge HK, Scudiero DA, Jensen PB, Shoemaker RH, and Sehested M (2005) Substituted purine analogues define a novel structural class of catalytic topoisomerase II inhibitors. Cancer Res 65:7470-7477.
14. Jensen PB, Christensen IJ, Sehested M, Hansen HH, and Vindelov L (1993) Differential cytotoxicity of 19 anticancer agents in wild type and etoposide resistant small cell lung cancer cell lines. Br J Cancer 67:311-320.
15. Jensen PB and Sehested M (1997) DNA topoisomerase II rescue by catalytic inhibitors: a new strategy to improve the antitumor selectivity of etoposide. Biochem Pharmacol 54:755-759.
16. Klebe G, Abraham U, and Mietzner T (1994) Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. J Med Chem 37:4130-4146.
17. Kobayashi M, Adachi N, Aratani Y, Kikuchi A, and Koyama H (2001) Decreased topoisomerase IIα expression confers increased resistance to ICRF-193 as well as VP-16 in mouse embryonic stem cells. Cancer Lett 166:71-77.
18. Kohn KW and Grimek-Ewig RA (1973) Alkaline elution analysis, a new approach to the study of DNA single-strand interruptions in cells. Cancer Res 33:1849-1853.
19. Kubinyi H, Hamprecht FA, and Mietzner T (1998) Three-dimensional quantitative similarity-activity relationships (3D QSiAR) from SEAL similarity matrices. J Med Chem 41:2553-2564.
20. Larsen AK, Escargueil AE, and Skladanowski A (2003) Catalytic topoisomerase II inhibitors in cancer therapy. Pharmacol Ther 99:167-181.
21. Lindsley JE (2001) Use of a real-time, coupled assay to measure the ATPase activity of DNA topoisomerase II. Methods Mol Biol 95:57-64.
22. Morris SK, Baird CL, and Lindsley JE (2000) Steady-state and rapid kinetic analysis of topoisomerase II trapped as the closed-clamp intermediate by ICRF-193. J Biol Chem 275:2613-2618.
23. Rothenborg-Jensen L, Hansen HF, Wessel I, Nitiss JL, Schmidt G, Jensen PB, Sehested M, and Jensen LH (2001) Linker length in podophyllotoxin-acridine conjugates determines potency in vivo and in vitro as well as specificity against MDR cell lines. Anticancer Drug Des 16:305-315.
24. Sehested M and Jensen PB (1996) Mapping of DNA topoisomerase II poisons (etoposide and clerocidin) and catalytic inhibitors (aclarubicin, ICRF-187) to four distinct steps in the topoisomerase II catalytic cycle. Biochem Pharmacol 51:879-886.
25. Sehested M, Jensen PB, Sorensen BS, Holm B, Friche E, and Demant EJF (1993) Antagonistic effect of the cardioprotector (+)-1,2-bis(3,5- dioxopiperazinyl-1-yl)propane (ICRF-187) on DNA breaks and cytotoxicity induced by the topoisomerase II directed drugs daunorubicin and etoposide (VP-16). Biochem Pharmacol 46:389-393.
26. Wang H, Mao Y, Chen AY, Zhou N, LaVoie EJ, and Liu LF (2001) Stimulation of topoisomerase II-mediated DNA damage via a mechanism involving protein thiolation. Biochemistry 40:3316-3323.
27. Wang JC (2002) Cellular roles of DNA topoisomerases: a molecular perspective. Nat Rev Mol Cell Biol 3:430-440.
28. Wessel I, Jensen LH, Renodon-Corniere A, Sorensen TK, Nitiss JL, Jensen PB, and Sehested M (2002) Human small cell lung cancer NYH cells resistant to the bisdioxopiperazine ICRF-187 exhibit a functional dominant Tyr165Ser mutation in the Walker A ATP binding site of topoisomerase IIα. FEBS Lett 520:161-166.
29. Wilstermann AM and Osheroff N (2003) Stabilization of eukaryotic topoisomerase II-DNA cleavage complexes. Curr Top Med Chem 3:321-338.
30. Yang X, Li W, Prescott ED, Burden SJ, and Wang JC (2000) DNA topoisomerase IIβ and neural development. Science (Wash DC) 287:131-134.
31. Zhang H, D'Arpa P, and Liu LF (1990) A model for tumor cell killing by topoisomerase poisons. Cancer Cells 2:23-27.
32. Zhou N, Xiao H, Li TK, Nur EKA, and Liu LF (2003) DNA damage-mediated apoptosis induced by selenium compounds. J Biol Chem 278:29532-29537.